Global Oligonucleotide Therapeutics Market 2025 by Company, Regions, Type and Application, Forecast to 2031

Global Oligonucleotide Therapeutics Market 2025 by Company, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Oligonucleotide Therapeutics market size was valued at US$ 12850 million in 2024 and is forecast to a readjusted size of USD 9600 million by 2031 with a CAGR of 3.6% during review period.

Oligonucleotide therapeutics are a class of precision medicines composed of short DNA or RNA sequences designed to specifically target and modulate the expression of genes involved in disease processes. These therapies can act by silencing, inhibiting, or correcting genetic abnormalities at the molecular level, offering a highly targeted approach to treat various conditions such as genetic disorders, cancers, and viral infections. Oligonucleotide therapeutics include antisense oligonucleotides, small interfering RNA (siRNA), and aptamers, and they represent a promising area of drug development due to their ability to address previously untreatable diseases.

Key driver of the oligonucleotide therapeutics market is the growing prevalence of genetic and rare diseases that require precise and targeted treatment options. Advances in genomics and personalized medicine have fueled interest in oligonucleotide therapies, which can directly modulate gene expression and offer solutions for conditions that were previously difficult to treat. The success of approved oligonucleotide drugs, such as antisense oligonucleotides and siRNA therapies, has increased confidence in this field, leading to more investments and research in developing novel treatments for a wide range of diseases, including cancers and neurological disorders.

One significant challenge in the oligonucleotide therapeutics market is the complexity of delivering these molecules effectively to target cells or tissues. Oligonucleotides are large, negatively charged molecules that face hurdles in stability, bioavailability, and efficient cellular uptake. Developing delivery systems that can ensure targeted and sustained delivery while minimizing immune responses or off-target effects remains a critical challenge. Additionally, the high costs associated with research, development, and manufacturing of oligonucleotide-based drugs pose financial challenges, limiting accessibility and widespread adoption, especially in resource-constrained healthcare settings.

Europe is the largest consumption place, with a consumption market share nearly 44.61% in 2023. Following Europe, North Americas is the second largest consumption place with the consumption market share of 34.9%. The global key companies of oligonucleotide therapeutics include Pfizer, Moderna Therapeutics, BioNTech, Biogen, Alnylam, Sarepta Therapeutics, Jazz Pharmaceuticals, Nippon Shinyaku, Novartis, Sobi, Ionis Pharmaceuticals, etc. In 2023, the global top five players had a share approximately 97.87% in terms of revenue.

This report is a detailed and comprehensive analysis for global Oligonucleotide Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Oligonucleotide Therapeutics market size and forecasts, in consumption value ($ Million), 2020-2031

Global Oligonucleotide Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2020-2031

Global Oligonucleotide Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031

Global Oligonucleotide Therapeutics market shares of main players, in revenue ($ Million), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Oligonucleotide Therapeutics

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Oligonucleotide Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Oligonucleotide Therapeutics market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Antisense Oligonucleotides (ASO)
siRNA
mRNA

Market segment by Application
Neuromuscular Diseases
hATTR
COVID-19
Other

Market segment by players, this report covers
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Oligonucleotide Therapeutics product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Oligonucleotide Therapeutics, with revenue, gross margin, and global market share of Oligonucleotide Therapeutics from 2020 to 2025.

Chapter 3, the Oligonucleotide Therapeutics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Oligonucleotide Therapeutics market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Oligonucleotide Therapeutics.

Chapter 13, to describe Oligonucleotide Therapeutics research findings and conclusion.